IL2 and COVID-19: As the IL2-AIS was initially identified in the DILfrequency study using a targeted panel of 565 transcripts designed for profiling T and NK cells [4], we sought to understand the observed changes in the broader transcriptional landscape of immune cells in COVID-19 patients.